Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.66 USD
Change Today -0.044 / -0.18%
Volume 5.1K
TKPYY On Other Exchanges
As of 12:31 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutic-sp adr (TKPYY) Key Developments

Takeda Pharmaceutical Co. Consolidate its U.S. Vaccine Operations in Boston/Cambridge Area; Closes Facilities in Madison, Fort Collins, Bozeman and Deerfield, Illinois

Takeda Pharmaceutical Co. announced that it is consolidating its U.S. vaccine operations in the Boston/Cambridge area. The company closing facilities in Madison; Fort Collins, Colorado; Bozeman, Montana; and Deerfield, Illinois.

Takeda Pharmaceutical Company Limited Submits New Drug Application for ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited announced that a new drug application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. The NDA submission was based on the pivotal Phase 3 trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Patients continue to be treated in this trial and evaluated for long-term outcomes.

Takeda Pharmaceutical Company Limited Announces Executive Appointments

Takeda Pharmaceutical Company Limited announced the appointment of Yasuchika Hasegawa as Director, Chairman of the Board from his previous position Representative Director, Chairman of the Board. The company also appointed Andrew Plump, M.D., Ph.D. as Director, Chief Medical and Scientific Officer from his previous position Corporate Officer and Yasuhiko Yamanaka as Corporate Auditor from his previous position Managing Director.

Takeda Announces the Resignation of CFO François-Xavier Roger

Takeda Pharmaceutical Company Limited announced that François-Xavier Roger has resigned effective June 26, 2015 to become chief financial officer of Nestlé S.A.

Takeda Pharmaceutical Company Limited Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM

Takeda Pharmaceutical Company Limited Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $24.66 USD -0.044

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.92 USD +0.2314
Baxter International Inc $37.95 USD +0.245
Becton Dickinson and Co $148.74 USD +2.41
Biogen Inc $314.56 USD +5.13
Merck KGaA €92.43 EUR +0.89
View Industry Companies

Industry Analysis


Industry Average

Valuation TKPYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 152.9x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at